Evaluating coronary artery disease—where does EBCT fit in?: Reply  by Shavelle, David M & Budoff, Matthew J
ity and specificity of technetium-stress testing. The authors refer to
a meta-analysis of studies examining exercise nuclear testing (2). In
this pooled analysis, nuclear testing had a sensitivity of 87% and a
specificity of 64%. Using this sensitivity and specificity, and
assuming a disease prevalence of 20%, we calculated a positive
predictive value of 38%, a negative predictive value of 95% and an
accuracy of 69% for technetium-stress testing. The positive like-
lihood ratio was 2.4, and the negative likelihood ratio was 0.2.
Thus, when the diagnostic test characteristics are recalculated
using the higher sensitivity and specificity from the literature, it
appears that technetium-stress testing may be a better screening
test than EBCT to identify patients with CAD.
A third issue is that the meta-analysis (2) referred to by Shavelle
et al. (1) also published test characteristics for exercise echocardi-
ography, reporting a pooled sensitivity and specificity of 85% and
77%, respectively. Using these data, we calculated the diagnostic
test characteristics for exercise echocardiography in a population
with a disease prevalence of 20% (Table 1). The positive and
negative predictive values were 48% and 95%, respectively; accu-
racy was 79%; and the positive and negative likelihood ratios were
3.7 and 0.2, respectively. Thus, using the pooled sensitivity and
specificity from the literature, exercise echocardiography may well
be the best of the four diagnostic tests.
Finally, because of the relatively small number of patients
studied by Shavelle et al., it would have been helpful if the authors
had included 95% confidence intervals (CIs) for the diagnostic test
characteristics they cited. Although the point estimates they
reported suggest that EBCT has reasonable test characteristics,
CIs for these numbers may be wide, and there may be no
statistically significant difference among the various diagnostic
tests.
In conclusion, EBCT has several important limitations when
used for the diagnosis of CAD. It is a costly procedure, and it
provides no information regarding the functional significance of
any lesions that may be present. Before EBCT is widely employed
as a screening test for CAD, the evidence in favor of this test must
be carefully scrutinized. Investigators should report on diagnostic
test characteristics in populations where the disease prevalence is
reflective of the populations in which the tests will eventually be
used. In addition, similar, but larger studies, need to be performed
in lower-risk populations to provide precise point estimates of
diagnostic test characteristics as well as narrow CIs for these
numbers.
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REPLY
We appreciate the comments of Drs. Sheppard and Eisenberg
regarding our recent publication evaluating the use of electron
beam computed tomography (EBCT) in symptomatic patients
undergoing exercise stress testing and coronary angiography (1).
The study population was indeed at high risk for coronary artery
disease (CAD) as all patients were symptomatic with presumed
ischemic chest pain and were referred for coronary angiography by
their treating physicians. This population would therefore not be
reflective of patients referred for EBCT to exclude the presence of
CAD. By assuming a disease prevalence of 20%, compared to the
prevalence of 69% in our study, Drs. Sheppard and Eisenberg
found EBCT to have a negative predictive value of 98%, indicating
an excellent ability to exclude CAD. Using values for sensitivity
and specificity from a meta-analysis (2), they found technetium-
stress testing to have the highest positive likelihood ratio among
the testing methods, indicating a superior ability to diagnose CAD
in this lower-risk population. We agree with these calculations and
conclusions, but we stress that our patient population was signif-
icantly different from one with a disease prevalence of 20%.
Therefore, our study did not evaluate a patient population referred
to EBCT for the purpose of screening for CAD.
A significant limitation of our report was the relatively low
sensitivity and specificity for technetium-stress testing. As outlined
in the Discussion section, possibilities for this include imaging
defects secondary to diaphragmatic and/or breast attenuation, the
lack of electrocardiograph (ECG)-gating and delayed image ac-
quisition after injection of the nuclear tracer agent. However, as
Drs. Shepard and Eisenberg point out, another significant issue is
the relatively small number of patients in our study (n 5 97),
which may be the main reason for these findings.
The suggestion that exercise echocardiography may be the best
noninvasive diagnostic test because of its highest positive likeli-
hood ratio (3.7) is possible, but this modality was not evaluated in
our study.
The 95% confidence intervals (CIs) for the characteristics of
each testing method are shown in Table 1. As Drs. Sheppard and
Eisenberg suggest, the CIs for several of the testing methods are
relatively wide. We agree that additional, larger studies are needed
to further evaluate the utility of EBCT coronary scanning.
Table 1. 95% Confidence Intervals for the Characteristics of
Each Testing Method
Testing
Method
Sensitivity
(%)
95% CI
Specificity
(%)
95% CI
Accuracy
(%)
95% CI
PPV
(%)
95% CI
NPV
(%)
95% CI
Treadmill-ECG 76 60 71 81 53
66, 88 42, 78 62, 80 71, 91 36, 70
Technetium-
stress
78 67 74 83 57
68, 88 50, 84 65, 83 74, 92 41, 73
EBCT 96 47 80 80 82
91, 100 29, 65 72, 88 71, 89 64, 100
Treadmill-ECG
and EBCT
72 83 75 91 57
61, 83 70, 96 66, 84 83, 99 42, 72
CI 5 confidence interval; EBCT 5 electron beam tomography; ECG 5 electrocar-
diograph; NPV 5 negative predictive value; PPV 5 positive predictive value.
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Dr. Danias points out similar concerns to Drs. Shepard and
Eisenberg regarding the low sensitivity and specificity for
technetium-stress testing. As discussed previously, this is clearly a
limitation of our study and could potentially be resolved by
evaluating a larger number of patients. Dr. Danias also expresses
concern over the 27 patients who had a positive EBCT scan and a
negative treadmill-ECG and were therefore classified as having a
negative “test” for the combined approach (EBCT combined with
treadmill-ECG). The mean coronary calcium (CC) score for these
patients as determined by the Agatston method (3) was 394, range
1 to 1420. For this combined approach, a positive EBCT was
defined as a CC score .0 in order to maximize sensitivity. Raising
the CC score cutoff would lower sensitivity and raise specificity, as
shown in Table 3 of our article (1). We agree with Dr. Danias that
our study did not include a cost-effectiveness analysis, which would
be useful in further determining the utility of EBCT in the
evaluation of symptomatic patients. However, EBCT does have a
relatively low cost, and other studies have documented its benefit
in the diagnostic evaluation of patients with symptoms suggestive
of CAD (4,5).
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Molecular Effects of
HMG-CoA Reductase Inhibitors
on Smooth Muscle Cell Proliferation
We read with great interest the report by Indolfi et al. (1). The
data reported are very interesting because, to the best of our
knowledge, this is the first report demonstrating simultaneously
that: 1) a hydroxymethylglutaryl Coenzyme A (HMG-CoA)
reductase inhibitor blocks smooth muscle cell (SMC) proliferation
in vitro; 2) this inhibitor potently reduces neointimal formation
induced by vascular injury in vivo; and 3) the in vitro and in vivo
effects are completely abolished by mevalonate but not by choles-
terol. The investigators linked the antiproliferative effect of the
HMG-CoA reductase inhibitor to suppression of Ras farnesyla-
tion and the Ras-mediated MAPK (mitogen-activated protein
kinase) transduction pathway.
However, we have evidence that the HMG-CoA reductase
inhibitors have several targets (not only the Ras farnesylation) in
the SMC proliferation, which have not been completely identified
yet. This is in agreement with data of Grandaliano et al. (2), who
have described that the inhibition of cell proliferation by simva-
statin was not reversed by farnesol. Furthermore, Wejde et al. (3)
have demonstrated that farnesol failed to promote the growth of
compactin (a lovastatin analogue)-blocked cultured breast cancer
cells. In addition, our data have shown that despite lovastatin-
mediated inhibition of Ras farnesylation, the activation of MAPK
is only partially inhibited (4).
Several lines of evidence suggest that the endogenous basic
fibroblast growth factor (bFGF), known to be synthesized by
vascular SMC (5,6), plays an important role in the stimulation of
SMC proliferation that occurs during atherogenesis (7) and in
response to vessel wall injury (8). Furthermore, it has been shown
that i) bFGF, released from arterial SMC after injury, is a potent
mitogen (9) and ii) bFGF- or injury-induced SMC proliferation is
significantly inhibited by anti-bFGF antibodies (10). Thus, bFGF
expressed by vascular SMC is a strong mitogenic factor stimulating
SMC in an autocrine and paracrine manner. However, no studies
about the association between the content of the endogenous
bFGF and the HMG-CoA reductase inhibitor treatment of SMC
were reported.
Thus, we have analyzed the effects of lovastatin on growth
factor-induced DNA synthesis in a dose-dependent manner in
human coronary SMC in vitro as well as the influence of the
HMG-CoA reductase inhibitor on the expression of the endoge-
nous bFGF. Our [3H] thymidine and cell-counting experiments
showed that lovastatin caused a reduction of the DNA synthesis
and proliferation in human SMC in a dose-dependent manner.
Mevalonate (50 mmol/liter) reduced the inhibition produced by
lovastatin (5 mmol/liter) by 90%. In contrast, addition of choles-
terol did not overcome the inhibition, demonstrating that these
effects are not cholesterol-dependent. Furthermore, lovastatin
treatment of SMC (in the concentration range that inhibited SMC
proliferation) significantly (p , 0.05) reduced the level of the
endogenous bFGF to 55% of control cells. The lovastatin-induced
effects were reversed by mevalonate but not by cholesterol.
These findings suggest that HMG-CoA reductase inhibitors
suppress cell proliferation by downregulation of the expression of
the endogenous bFGF. In light of the present findings of Indolfi
et al. (1) and our group, it is likely that HMG-CoA reductase
inhibitors target several points in the mitogenic pathway of SMC.
First, as described by Indolfi et al. (1), HMG-CoA reductase
inhibitors block the farnesylation of Ras and the Ras- mediated
activation of MAPK. Second, the inhibitors suppress the endog-
enous expression of the strong mitogen bFGF. Overall, we agree
with the investigators that the growth-inhibitory effects of HMG-
CoA reductase inhibitors are cholesterol-independent. The under-
lying mechanisms, however, still remain to be elucidated in further
studies.
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